Breaking News

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

Genius AI Detection Receives FDA Clearance – New Deep Learning-based Software Designed to Help Radiologists Detect Subtle Potential Cancers in Breast Tomosynthesis Images

This new technology, represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius® 3D Mammography™ exam.

Passio Pump Drainage System Granted 510(k) for Additional Indication for Home Use

The Passio Pump Drainage System consists of the Passio Catheter, a Handheld Control Unit (pump) and a Disposable Collection Kit, which includes a redressing kit, for drainage of recurrent and symptomatic pleural effusion.

Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

Boston Scientific notes SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases.

Stratus Medical Announces 2 New US Patents Issued for the Nimbus® RF Multitined Expandable Electrode

September 14, 2020

Stratus Medical, a company focused on advancing radiofrequency ablation (RFA) treatment for chronic pain, announced today that the United States Patent and Trademark Office has granted two new patents related to its Nimbus® RF Multitined Expandable Electrode. U.S. Patent No. 10,716,618, titled System and Methods for Tissue Ablation, issued on July 21, 2020, and U.S. Patent No. 10,736,688, titled Methods and Systems for Spinal Radio Frequency Neurotomy, issued on August 11, 2020.

Stratus Medical’s newest patents collectively contain 146 claims directed to radiofrequency systems. These claims provide broad protection for Stratus Medical’s Nimbus technology. Stratus Medical now holds two U.S. patents and 14 patents outside the U.S. on this technology, with two additional patent applications pending in the U.S. and 10 patent applications pending outside the U.S.

Bret Boudousquie, Stratus Medical CEO shared, “We see great opportunity to help patients suffering from chronic pain and improve quality of life as interventional pain medicine physicians expand their utilization of radiofrequency ablation (RFA) to treat pain in the spine, knee and sacroiliac joint. We are pleased to secure these new patents to protect our proprietary Nimbus technology as procedural protocols shift from traditional RFA needles to the Nimbus device, which provides a large volume lesion with the goal to improve patient outcomes. Nimbus is rapidly building market share due to its numerous clinical advantages over other large volume lesion RFA options, including faster procedure times and lower cost.”

 

Latest Posts

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.